Analyst Rating Update on Shire plc (SHPG)

Shire plc (NASDAQ:SHPG) : Zacks Investment Research ranks Shire plc (NASDAQ:SHPG) as 3, which is a Hold recommendation. 10 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.38, which indicates as a Strong Buy.

Shire plc (NASDAQ:SHPG) : The most positive equity analysts on Shire plc (NASDAQ:SHPG) expects the shares to touch $325, whereas, the least positive believes that the stock will trade at $174 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $248.92 with an expected fluctuation of $40.26 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Morgan Stanley assumes its rating on Shire plc (NASDAQ:SHPG). The rating major has initiated the coverage with overweight rating on the shares. The rating by the firm was issued on June 3, 2016.

Shire plc (NASDAQ:SHPG): stock turned positive on Tuesday. Though the stock opened at $169.31, the bulls momentum made the stock top out at $171.28 level for the day. The stock recorded a low of $168.87 and closed the trading day at $171, in the green by 3.86%. The total traded volume for the day was 2,074,173. The stock had closed at $164.64 in the previous days trading.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.